| What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? | |
| | |
MedLine Citation:
|
PMID: 20686417 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Statin therapy is widely used in treatment and prevention of cardiovascular disease (CVD). It is well established that statin therapy is not associated with significant increase in high-density lipoprotein cholesterol (HDL-c) or significant decrease in triglyceride level. Importantly, emerging evidence has suggested that low HDL-c and high triglyceride are strong risk factors associated with CVD. Niacin is a unique lipid-lowering medication with a capacity to lower low-density lipoprotein cholesterol (LDL-c), triglyceride and increase HDL-c. In this context, there is considerable interest in trials involving niacin as monotherapy and in association with statins. Recent trials showed that the combination of statin and niacin is an effective treatment not only for dyslipidaemia (high LDL-c, high triglyceride and low HDL-c) but also for carotid intima-media thickness, one of the important features of atherosclerosis. Furthermore, niacin is distinguished by its unique capacity to effectively lower lipoprotein (a) [Lp(a)] levels. Flushing is the only factor that limits the wide use of niacin. The combination of statin and niacin has potential as a future treatment of atherogenic dyslipidemias; however, further evidence is needed. Importantly, the impact of niacin and statin on insulin sensitivity is not yet known. This article projects the potential benefits of current and possible future niacin clinical trials. |
| | |
Authors:
|
Mohamed H Ahmed |
Related Documents
:
|
818017 - Bacterial interference: effects of oral antibiotics on the normal throat flora and its ... 15671087 - Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. 11236277 - Cardiovascular disease: a historic perspective. 20196737 - High-density lipoprotein-raising strategies: update 2010. 10875637 - Effect of dietary selenium and vitamin e on the ultrastructure and atp concentration of... 21429727 - Lipid redistribution by α-linolenic acid-rich chia seed inhibits stearoyl-coa desatura... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of cardiovascular medicine (Hagerstown, Md.) Volume: 11 ISSN: 1558-2035 ISO Abbreviation: J Cardiovasc Med (Hagerstown) Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-09-30 Completed Date: 2011-01-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101259752 Medline TA: J Cardiovasc Med (Hagerstown) Country: United States |
Other Details:
|
Languages: eng Pagination: 858-60 Citation Subset: IM |
Affiliation:
|
Chemical Pathology Department, Southampton University Hospitals NHS Trust, Southampton, UK. elziber@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
blood Cardiovascular Diseases / blood, etiology, prevention & control* Carotid Artery Diseases / complications, drug therapy Cholesterol, HDL / blood Cholesterol, LDL / blood Drug Therapy, Combination Evidence-Based Medicine Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Hyperlipidemias / blood, complications, drug therapy* Hypolipidemic Agents / therapeutic use* Lipoprotein(a) / blood Niacin / therapeutic use* Treatment Outcome Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Hypolipidemic Agents; 0/Lipoprotein(a); 0/Triglycerides; 59-67-6/Niacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fracture of coronary artery sirolimus eluting stent with formation of four aneurysms.
Next Document: Trileaflet pulmonary valve atresia.